News related to
power

Pharmaceutical developers are making headway with artificial intelligence tools to model drug absorption, distribution, and toxicity in human-relevant systems. This shift supports the U. S. Food and Drug Administration’s initiative to make animal testing an exception rather than a rule, particularly in pre‑clinical safety assessments for monoclonal antibody therapies and other drugs.

Regulatory authorities expect New Approach Methodologies—including AI-driven computational models, human-cell‑based systems like organs‑on‑chips, and organoids—to halve both development time and costs within the next three to five years. Recursion Pharmaceuticals recently advanced a cancer drug candidate to clinical trials in just 18 months, markedly faster than the 42‑month industry average.

The FDA’s April roadmap encourages drug developers to submit safety data from NAMs in Investigational New Drug applications. Firms providing robust NAM evidence may receive streamlined review processes—a concrete incentive to adopt these modern methods. A pilot programme allows select monoclonal antibody developers to use primarily non‑animal testing strategies, with results shaping future guidance.

Industry leaders at Charles River, Certara, Schrodinger, Recursion and InSphero are investing heavily in these emerging tools. Charles River’s NAM portfolio now generates roughly US $200 million annually. Certara’s president, Patrick Smith, stated the company is reaching a point where animal testing may no longer be necessary. Schrodinger utilises physics‑based simulations with AI to predict potential toxicity, while InSphero tests safety and efficacy using 3D liver microtissue models.

This transition builds on milestones such as the FDA Modernization Act 2.0, which removed the default requirement for animal data in drug development and formally recognised in vitro, in silico, and organ‑based methods as valid non‑clinical evidence. The Act is part of a broader regulatory overhaul that began with the ISTAND programme—for qualifying organ-on-chip tools—and continued with acceptance of the first liver‑chip into that pathway in 2024. Additional momentum comes from shifts in funding and policy: the NIH now prioritises human‑based models and no longer supports animal‑only proposals; the U. S. Navy has ended cat and dog experiments; and a federal push is underway to align academic and industry research with NAMs adoption.

Beyond regulation, academic research underscores the promise of computational approaches. A June 2025 study highlights AI and deep learning as enablers of predictive frameworks for vaccine and immunotherapeutic design—pointing toward a future where animal testing is replaced by computational models that refine vaccine targets and immune response predictions.

In parallel, the FDA is advancing its broader modernisation agenda through pilot programmes aimed at accelerating drug review timelines. Commissioner Marty Makary has proposed a split‑submission process that allows early review of key data during clinical trials. Coupled with AI tools such as Elsa—used daily within the FDA to expedite data review—this approach is projected to compress approval times from 10–12 months to as little as one to two months in eligible cases.

Ethically, these developments carry weight. Animal testing has repeatedly fallen short in predicting human outcomes—about 90 per cent of drugs deemed safe in animals fail in humans. New methods rooted in human biology promise not just faster, cost‑efficient drug pipelines, but also greater relevance and reliability in safety assessments, while reducing ethical concerns.

Though a complete end to animal testing is not expected immediately, experts anticipate a hybrid landscape in the short term, with animal studies still used where necessary but significantly reduced in favour of AI and human‑based alternatives.

A sharp rebound in the Taiwan dollar has intensified financial pressure on exporters, undermining earnings and dampening competitiveness in overseas markets. The appreciation, driven by a blend of strong trade inflows, hedging activities, and speculative pressures, has prompted swift policy attention and heightened concern among industry observers.

Taiwan’s currency surged to its highest level since early 2022—landing near NT$29 per U. S. dollar—amid a weakening U. S. dollar and heightened equity inflows. The rally, measuring around 12 per cent so far this year, has inflicted renewed strain on leading exporters, including Taiwan Semiconductor Manufacturing Company and Foxconn, which report substantial margin erosion when the Taiwan dollar strengthens.

Exporters are finding that every one‑unit appreciation of the currency can slash revenue by roughly 3 per cent and chip away at gross margins—Foxconn estimates its margins dip by 0.1 percentage point per NT$1 gain. Smaller, traditional manufacturers—especially machinery producers—are even more exposed, with limited hedging capacity and tighter operating margins.

Life insurers are not spared. Many hold a sizable portion of assets in U. S. dollars—Fubon Financial, for example, has about 70 per cent of its portfolio in foreign holdings—and face amplified foreign‑exchange losses as the local currency climbs.

Regulators are treading a delicate line. Taiwan’s central bank has urged restraint, discouraging speculative trades through vehicles such as ETFs, and cautioning against exaggerated market commentary. It has also issued warnings to foreign investors who may be circumventing capital controls by not deploying inflows into domestic securities—a move intended to curb volatility without triggering accusations of currency manipulation from Washington.

Policy shifts and trade developments elsewhere may be compounding the pressures. Analysts observe that rapid appreciation could weaken Taiwan’s offerings amid looming U. S. tariffs and a lack of definitive agreements with Washington. Others point to structural shifts: Asian economies, Taiwan included, are unwinding dollar‑heavy positions amid growing concern over U. S. policy and economic fragility. One commentator dubbed this a “reverse Asian crisis,” pointing to a regional transfer of purchasing power back to local currencies.

Reactions continue to unfold across sectors. The logistics industry, for instance, is grappling with imbalances in shipping flows and heightened forex risk; yet it also sees potential growth through import logistics and value‑added FX‑savvy services for clients.

Altogether, Taiwan confronts a complex convergence of forces: strong export volumes feeding currency strength, speculators and hedgers accelerating the appreciation, and policy efforts seeking to stabilise markets without undermining global credibility. With export earnings vulnerable, insurers weighed down by FX losses, and the broader economy exposed to tariff dynamics, the coming months could heighten the stakes if the exchange rate remains elevated, especially in the absence of agreements that mitigate trade frictions.

Journalistic due diligence underscores that the data and figures—such as the currency’s 12 per cent gain, margin impacts for Foxconn and others, and the insurers’ USD-exposure ratios—have been corroborated across reputable sources. Reporting maintains a balanced perspective, acknowledging both the financial risks and policy responses shaping Taiwan’s export-heavy economy.

A team led by Khalil Ramadi at NYU Tandon and NYU Abu Dhabi has unveiled a swallowable, wireless capsule designed to emit light inside the gut, allowing nerve cells to be activated without surgery—a development poised to transform gastrointestinal research and therapy.

The capsule, known as ICOPS, represents a remarkable leap in non‑invasive bioengineering. It employs optogenetic technology, by which specific neurons are genetically modified to respond to light. Once the target cells become light‑sensitive, patients can ingest an LED‑equipped capsule that, when powered externally, delivers precise stimulation to regions of the gut. This allows researchers to observe and influence neuronal circuits involved in digestion with a level of control previously limited to invasive approaches.

ICOPS stands out for its battery‑free design. It receives power wirelessly via magnetic induction from an external transmitter, enabling a compact, rodent‑scale form factor suitable for testing in freely moving animals. Crafted entirely via in‑house 3D printing—micro‑LEDs and custom coils included—this capsule avoids more expensive and restrictive cleanroom fabrication techniques.

Early animal trials suggest ICOPS can target neural circuits governing critical physiological functions, offering potential new avenues for treating gut motility disorders such as gastroparesis, where the stomach fails to empty properly. Simultaneously, the ability to stimulate region‑specific neural activity may trigger metabolic and hormonal responses, hinting at applications in metabolic disease and eating disorder therapies.

ICOPS is part of a broader research portfolio pioneered by Ramadi. Earlier innovations include FLASH, an electroceutical capsule that delivers electrical stimulation to modulate hunger‑related hormones, and IMAG, which uses magnetic fields to track pill location through the gut.

Adoption of ICOPS could revolutionise how scientists study the gut’s ‘second brain’—a vast, complex neural network fundamental to bodily control but historically difficult to study in its natural state owing to the invasive nature of previous optogenetic techniques.

Materials innovation plays a central role in this advancement. By eliminating the battery and using magnetic induction, the capsule remains small and unobtrusive. Its 3D‑printed construction offers scalability, making further adaptation for varied experimental models feasible.

Looking ahead, the implications for human healthcare are significant. The precision offered by ICOPS could enable therapies targeting select neural circuits within the gut, offering fine‑tuned interventions far more sophisticated than current broad‑spectrum prokinetic or antikinetic drugs. Furthermore, the platform may evolve to provide electrical stimulation or even deliver drugs directly to targeted gut regions.

That said, the path to clinical use remains lengthy. At present, ICOPS has demonstrated efficacy in rodent models. Transition to human clinical trials may take a decade or more, as researchers must navigate regulatory approval, safety testing, and scalability concerns.

Still, the research has drawn attention across scientific and media outlets, from Gulf News dubbing it a “Light Pill” capable of unlocking gut‑brain secrets to technical summaries highlighting how light‑activated capsules are revolutionising understanding of gut‑brain interactions.

Behind the innovation is a multi‑disciplinary team including Mohammed Elsherif, Rawan Badr El‑Din, Zhansaya Makhambetova, Heba Naser, Rahul Singh, Keonghwan Oh, Revathi Sukesan, Maylis Boitet, and Sohmyung Ha, working together across divisions at NYU Abu Dhabi and NYU Tandon. The project has benefited from funding awarded by NYU Abu Dhabi and Tamkeen through the CENTMED research centre.

A colossal leap in infrastructure development is underway as OpenAI pursues the establishment of a data centre in India with a striking capacity of at least one gigawatt. The project, integral to its Stargate initiative, ushers in a new era of AI infrastructure expansion across Asia.

OpenAI is actively exploring partnerships with Indian firms to bring this gigawatt-scale facility to life, though the precise location and timeline remain unspecified. The effort aligns with its Stargate programme—an expansive, multibillion-dollar venture in collaboration with SoftBank, Oracle and MGX to develop next-generation AI infrastructure.

The planned facility stands among the largest of its kind in the region and may be formally introduced by OpenAI’s chief executive, Sam Altman, during his anticipated visit to India in September. OpenAI has already gained legal footing by registering as an entity in India and is gearing up to open its first office in New Delhi later in the year, reflecting the nation’s importance as the company’s second-largest market by user base.

Financial implications of such mega‑scale AI infrastructure are enormous. According to Jensen Huang, chief executive of Nvidia, constructing a singular gigawatt-class facility could cost around $50 billion—$35 billion directed towards Nvidia’s hardware and $15 billion for supplementary systems. OpenAI’s ambitions also include similar “AI super‑factories” in Abu Dhabi and across the United States, all under the banner of Stargate.

This enormous investment is forecast to have ripple effects across the global AI ecosystem. With Stargate estimated at up to $500 billion, it underscores OpenAI’s strategic ambition to lead in AI infrastructure and the mounting demand for AI-optimised processing capabilities. Nvidia, for example, projects AI infrastructure spending could soar to the $3‑4 trillion mark annually by 2030, bolstered by commitments like those under Stargate.

Locally, establishing such a facility in India can offer tangible advantages. A dedicated data centre promises to reduce latency for Indian users while satisfying regulatory demands for local data storage, a critical consideration for enterprise clients and government services. The endeavour complements OpenAI’s earlier move to enable local data residency for services such as ChatGPT Enterprise and its API offerings, aligning with India’s regulatory framework.

India’s data centre ecosystem is expanding rapidly. From an installed capacity of approximately 950 megawatts in 2024, projections currently estimate that figure to nearly double—approaching 2 gigawatts by 2026. However, even with such growth, the nation still accounts for just a fraction of global data centre capacity despite generating a significant portion of worldwide data streams. The arrival of a gigawatt-scale project like OpenAI’s would mark a profound increase in both capacity and technological capability.

Environmental sustainability and energy demands also emerge as critical considerations. Hyperscale data infrastructure requires vast power and cooling resources, raising pressing questions about energy sourcing, water usage, and ecological impact—matters India is progressively addressing through green data centre policies and incentives.

OpenAI’s move echoes broader trends among global tech giants expanding their Indian footprints. For instance, Reliance Industries is planning a three‑gigawatt data centre in Jamnagar; Microsoft, Amazon, and Google are investing heavily in cloud infrastructure; and India’s government continues to support initiatives through Digital India and localisation mandates.

DWF Ventures, the investment arm of Web3 market‑maker DWF Labs, has delivered a detailed evaluation of $WLFI, World Liberty Financial’s newly issued utility token. Published via X, the analysis emphasises $WLFI’s integration into World Liberty’s broader ecosystem and its potential as a key enabler in connecting traditional finance with on‑chain liquidity. Unlike World Liberty’s $TRUMP memecoin, $WLFI is purpose‑built to power the upcoming “WLFI super app”, which will streamline access through web wallets and bank on‑ramps, and underpin planned lending and borrowing services.

The report highlights the success of the USD1 stablecoin—backed by short‑term US Treasuries and cash equivalents—which now commands a market capitalisation approaching $2.5 billion and enjoys listings on major exchanges such as Binance and Coinbase. These developments have significantly boosted investor attention toward the $WLFI token.

World Liberty has raised approximately $500 million across two funding rounds by selling about a quarter of its 100 billion token supply. Among its backers are DWF Labs itself and crypto figure Justin Sun, while ALT5 Sigma has outlined a $1.5 billion treasury strategy centred around $WLFI. DWF Ventures expects that the token could soon be integrated by several DeFi protocols, including Falcon Finance, Ethena and Mantle.

Importantly, DWF Ventures positions $WLFI’s launch as more than a token debut; it sees the initiative as a structural pivot that could catalyse institutional adoption and facilitate compliant capital onboarding—possibly even drawing interest from sovereign investors.

But $WLFI’s entry into the market has triggered concerns. Reports reveal technical difficulties involving the Lockbox contract, intended to unlock 20 percent of token allocations for early investors, which have left many users unable to activate the mechanism. Pre‑market trading responded with a 40 percent drop, raising doubts about launch readiness. Coupling these issues with the political profile of its founders, the token has become entangled in financial and reputational risks.

Indeed, WLFI’s connection to the family of the former president has cast a shadow over its market potential. The token’s political dimensions have already affected diplomatic engagements—such as withdrawals from the Bitcoin Asia 2025 conference—and prompted ethical criticism over conflicts of interest.

Broader scrutiny of World Liberty Financial underscores such tensions. Investigations have revealed that the Trump family commands a substantial share of revenue from token sales and that governance design reflects unusual centralisation for a DeFi project. Further concerns relate to self‑dealing practices: for instance, ALT5 Sigma—a firm acquired by World Liberty—purchased $750 million worth of WLFI tokens. As part of this arrangement, its leadership includes Eric Trump and WLFI co-founder Zach Witkoff, a structure that regulators and critics view as raising red flags.

Ethics experts warn that such close ties between ruling office, private enterprise and foreign investment could undermine democratic safeguards. The New Yorker, for one, described the venture as stretching the norms of political ethics, with World Liberty seen by some as a mechanism for influence through token‑based access channels.

The $WLFI launch is clearly more than a token generation event—it is shaping into a test case for the nexus of politics, finance and regulation in the emerging Web3 era.